Indications and results of sentinel lymph node biopsy in breast cancer: Changes observed in 2018 compared to 2012

Over the last 15 years, breast cancer (BC) treatment has undergone numerous changes, which have also affected the indications for Sentinel Lymph Node Biopsy (SLNB) as well as the procedures depending on its outcome. The aim of this study is to compare the results of the SLNB carried out at our Cente...

Full description

Saved in:
Bibliographic Details
Published in:Revista Española de medicina nuclear e imagen molecular (English ed.) 2022-11, Vol.41 (6), p.345-349
Main Authors: Merino San Martín, E.S., Frías Aldeguer, L., Ordás Álvarez, P., García Calvo, L., Escabias del Pozo, C., Domínguez Gadea, L., Martí Álvarez, C., Hernández Gutiérrez, A., Sánchez-Méndez, J.I.
Format: Article
Language:English
Subjects:
Axillary lymph-node dissection
Breast cancer
Cáncer de mama
Ganglio centinela
Linfadenectomía axillar
Neoadjuvant therapy
Sentinel lymph node
Terapia neoadyuvante
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Over the last 15 years, breast cancer (BC) treatment has undergone numerous changes, which have also affected the indications for Sentinel Lymph Node Biopsy (SLNB) as well as the procedures depending on its outcome. The aim of this study is to compare the results of the SLNB carried out at our Center during 2012, when we stopped performing an axillary lymph node dissection (ALND) after the finding of a micrometastasis, with those conducted in 2018, when we started applying Z011 criteria. We have performed a comparative retrospective observational study, including cN0 BC patients that underwent a SLNB in 2012 versus those that underwent this procedure in 2018. 174 patients from 2012 and 165 from 2018 were studied. We found significant differences between the two groups: in 2018 there were fewer lobular invasive cancers (14 vs 28) (P 
ISSN:2253-8089
2253-8089
DOI:10.1016/j.remnie.2021.09.009